Stay updated with breaking news from Nasdaq rlmd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Parsons Capital Management Inc. RI reduced its stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 949,841 shares of the company’s stock after selling 24,241 shares during […] ....
Silverarc Capital Management LLC acquired a new stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the company’s stock, valued at approximately $300,000. Silverarc Capital Management LLC owned […] ....
Silverarc Capital Management LLC acquired a new position in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 100,000 shares of the company’s stock, valued at approximately $300,000. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the […] ....
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CFO Maged Shenouda acquired 6,875 shares of Relmada Therapeutics stock in a transaction dated Wednesday, January 31st. The stock was bought at an average price of $4.06 per share, with a total value of $27,912.50. Following the completion of the purchase, the chief financial officer now directly […] ....
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) insider Chuck Ence bought 14,500 shares of the stock in a transaction dated Tuesday, January 30th. The stock was purchased at an average cost of $3.87 per share, for a total transaction of $56,115.00. Following the acquisition, the insider now owns 25,300 shares of the company’s stock, […] ....